- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03996226
A Food-Effect Study of E7386 in Healthy Participants
13 de noviembre de 2019 actualizado por: Eisai Inc.
A Phase 1 Food-Effect Study of E7386 in Healthy Subjects
The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of E7386 following single dose administration with and without a meal.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
17
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Texas
-
Austin, Texas, Estados Unidos, 78744
- PPD
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 55 años (Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Non-smoking, healthy participants at the time of informed consent.
- Body Mass Index (BMI) greater than (>) 18 and less than or equal to (<=) 30 kilogram per square meter (kg/m^2) at Screening.
Exclusion Criteria:
- Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per litre (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug
Females of childbearing potential who:
Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
- total abstinence (if it is their preferred and usual lifestyle)
- an intrauterine device or intrauterine hormone-releasing system
- a contraceptive implant
- an oral contraceptive (with additional barrier method) (Participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation)
- have a vasectomized partner with confirmed azoospermia
- Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
- Males who have not had a successful vasectomy (confirmed azoospermia) and their female partners meet the exclusion criteria No: 2, above. If the female partner is pregnant, then males who do not agree to use Barrier contraception (latex or synthetic condoms) throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation
- Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
- Any history of major surgery, e.g., intestinal resections, hepatectomy, nephrectomy, digestive organ resection that may affect absorption, metabolism or excretion of E7386.
- Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening
- Clinically significant ECG abnormality including a marked baseline prolongation of QT/corrected QT interval (QTc) (example: repeated demonstration of a QTc interval greater than (>) 500 milliseconds [msec]), or a family history of prolonged QTc syndrome or sudden death
- History of drug or alcohol misuse within 6 months prior to Screening, or who had a positive urine drug test at Screening or Baseline
- Diagnosed with acquired immune deficiency syndrome, or test positive for human immunodeficiency virus (HIV) at screening
- Active viral hepatitis (A, B or C) as demonstrated by positive serology at Screening
- Use of prescription drugs within 4 weeks prior to dosing
- Intake of over-the-counter medications within 2 weeks prior to dosing
- Intake of caffeinated beverages or food within 72 hours prior to dosing
- Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
- Participated in another clinical trial less than 4 weeks prior to dosing or was currently enrolled in another clinical trial
- Consumed grapefruit, starfruit, Seville oranges or their products within 7 days prior to dosing
- Consumed herbal preparations/medications including but not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng within 7 days prior to dosing
- Allergic to E7386 or any of the tablet's ingredients
- Known history of clinically significant drug or food allergies, or presently experiencing significant seasonal or perennial allergy at Screening.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: E7386: Fed + Fast
Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
|
E7386 oral tablets.
|
Experimental: E7386: Fast + Fed
Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
|
E7386 oral tablets.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Cmax: Maximum Observed Plasma Concentration for E7386
Periodo de tiempo: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for E7386
Periodo de tiempo: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
AUC0-t: AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386
Periodo de tiempo: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
AUC0-inf: Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for E7386
Periodo de tiempo: Day 1: 0-48 hours; Day 8: 0-48 hours
|
Day 1: 0-48 hours; Day 8: 0-48 hours
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
7 de junio de 2019
Finalización primaria (Actual)
29 de octubre de 2019
Finalización del estudio (Actual)
29 de octubre de 2019
Fechas de registro del estudio
Enviado por primera vez
21 de junio de 2019
Primero enviado que cumplió con los criterios de control de calidad
21 de junio de 2019
Publicado por primera vez (Actual)
24 de junio de 2019
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
14 de noviembre de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
13 de noviembre de 2019
Última verificación
1 de junio de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- E7386-A001-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Sí
Descripción del plan IPD
Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Sí
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre E7386
-
Eisai LimitedSuspendido
-
Eisai Inc.ReclutamientoNeoplasias AvanzadasEstados Unidos, Reino Unido
-
Eisai LimitedTerminado
-
Eisai Co., Ltd.Activo, no reclutandoUn estudio de E7386 en participantes con tumor sólido avanzado, incluido el cáncer colorrectal (CRC)Neoplasias colorrectales | Tumores Gastrointestinales | Neoplasias SólidasJapón
-
Medicines for Malaria VentureMahidol UniversityTerminadoPaludismo, falciparum | Paludismo, Vivax
-
Eisai Inc.ReclutamientoNeoplasias | Carcinoma Hepatocelular | Neoplasias Hepaticas | Neoplasias colorrectales | Neoplasias EndometrialesEstados Unidos, Taiwán, Francia, Japón, Corea, república de
-
Eisai Inc.Merck Sharp & Dohme LLCReclutamientoMelanoma | Carcinoma Hepatocelular | Neoplasias colorrectalesEspaña, Estados Unidos, Reino Unido, Japón, Francia